Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Dec;21(1):2491994.
doi: 10.1080/21645515.2025.2491994. Epub 2025 Apr 22.

Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination

Rachata Charoenwisedsil  1 , Saranath Lawpoolsri  2 , Pinyo Rattanaumpawan  3 , Daniel Y T Goh  4 , Gerard T Flaherty  5 , Thundon Ngamprasertchai  2
Affiliations
Review

Unveiling the complexity of vaccine hesitancy: A narrative review focusing on dengue vaccination

Rachata Charoenwisedsil et al. Hum Vaccin Immunother. 2025 Dec.

Abstract

Dengue vaccines face significant challenges, including safety concerns, which contribute to vaccine hesitancy. Addressing this complex issue requires targeted strategies to overcome existing barriers. Through an extensive review of current evidence, we identified key factors contributing to vaccine hesitancy and explored strategies to enhance global vaccine uptake. Four conceptual models and five assessment tools were identified to understand and measure vaccine hesitancy. Among the factors, "confidence" emerged as the most influential, followed by "complacency." Vaccine acceptance rates varied widely, ranging from 53% to 95%, depending on the region and population. Key determinants included population characteristics, concerns about efficacy and safety, among others. A comprehensive understanding of these factors is essential to improve vaccine acceptance, support dengue prevention efforts, and ensure public health success.

Keywords: Acceptance; CYD-TDV; TAK-003; dengue vaccine; travelers; vaccine hesitancy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

    1. Yang X, Quam MBM, Zhang T, Sang S.. Global burden for dengue and the evolving pattern in the past 30 years. J Travel Med. 2021;28(8). doi: 10.1093/jtm/taab146. - DOI - PubMed
    1. Freedman DO. A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travelers? J Travel Med. 2023;30(7):taad001. doi: 10.1093/jtm/taad132. - DOI - PubMed
    1. McGuinness SL, Leder K. Dengue severity in travellers: challenges and insights. J Travel Med. 2023;30(8). doi: 10.1093/jtm/taad146. - DOI - PMC - PubMed
    1. Torres-Flores JM, Reyes-Sandoval A, Salazar MI. Dengue vaccines: an update. BioDrugs. 2022;36(3):325–10. doi: 10.1007/s40259-022-00531-z. - DOI - PMC - PubMed
    1. Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C, Bravo L, Sirivichayakul C, Kosalaraksa P, Martinez Vargas L, et al. Three-year efficacy and safety of Takeda’s dengue vaccine candidate (TAK-003). Clin Infect Dis: Off Publ Infect Dis Soc Am. 2022;75(1):107–117. doi: 10.1093/cid/ciab864. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources